HUTCHMED (China) Ltd Files 6-K Report
Ticker: HMDCF · Form: 6-K · Filed: Dec 12, 2024 · CIK: 1648257
| Field | Detail |
|---|---|
| Company | Hutchmed (China) LTD (HMDCF) |
| Form Type | 6-K |
| Filed Date | Dec 12, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-k, foreign-private-issuer
TL;DR
HUTCHMED filed a routine 6-K, no major news.
AI Summary
HUTCHMED (China) Limited filed a Form 6-K on December 12, 2024. This filing is a report of a foreign private issuer and does not contain specific financial details or operational updates beyond its classification and filing status.
Why It Matters
This filing indicates HUTCHMED is meeting its reporting obligations as a foreign private issuer with the SEC, which is standard for companies listed on US exchanges.
Risk Assessment
Risk Level: low — The filing is a standard procedural report for a foreign private issuer and does not contain new material information that would impact risk.
Key Players & Entities
- HUTCHMED (China) Limited (company) — Filer of the report
- 001-37710 (other) — SEC Commission File Number
- 20241212 (date) — Filing date
FAQ
What type of filing is HUTCHMED (China) Limited submitting?
HUTCHMED (China) Limited is submitting a Form 6-K, which is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
When was this Form 6-K filed?
The Form 6-K was filed on December 12, 2024.
What is the SEC Commission File Number for HUTCHMED (China) Limited?
The SEC Commission File Number for HUTCHMED (China) Limited is 001-37710.
Does HUTCHMED file annual reports under Form 20-F or Form 40-F?
The filing indicates that HUTCHMED files annual reports under Form 20-F.
What is the principal executive office address of HUTCHMED (China) Limited?
The principal executive offices are located at 48th Floor, Cheung Kong Center, 2 Queen's Road Central, Hong Kong.
Filing Stats: 176 words · 1 min read · ~1 pages · Grade level 14.5 · Accepted 2024-12-12 06:02:49
Filing Documents
- hcm-20241212x6k.htm (6-K) — 20KB
- hcm-20241212xex99d1.htm (EX-99.1) — 39KB
- hcm-20241212xex99d1001.gif (GRAPHIC) — 4KB
- 0001648257-24-000095.txt ( ) — 66KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant's name into English) 48th Floor, Cheung Kong Center, 2 Queen's Road Central, Hong Kong (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F HUTCHMED (CHINA) LIMITED Form 6-K EXHIBIT INDEX Exhibit No. Description Exhibit 99.1 HUTCHMED announces Breakthrough Therapy Designation in China for ORPATHYS and TAGRISSO combination in certain lung cancer patients after disease progression on EGFR inhibitor therapy 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. HUTCHMED (CHINA) LIMITED By: /s/ Johnny Cheng Name: Johnny Cheng Title: Chief Financial Officer Date: December 12, 2024 3